Mysterious Fog in the US , Canada and UK: A dense, eerie fog with a "burning chemical-like smell" has spooked a good part of North America and parts of the United Kingdom and Canada. With social media amplifying all concerns, this phenomenon has sparked attention across all social media platforms. However, at the heart of this mysterious fog are a conjunction of natural events, social psychology, and environmental conditions that culminated in all the conspiracy theories and public health fears. Here's a closer look at the mysterious fog, its potential causes, and the societal response it has triggered.

Fog that Feeds Fear

The first reports of this "mysterious fog" came in from Florida where a resident said that they experienced respiratory symptoms, feverish warmth, and stomach cramps after contact with the fog. Similar stories started flooding social media, and within a day or two, a sinister force seemed to sweep across the United States, Canada, and parts of the UK. From Texas to Minnesota, people reported weird odors and health issues that they thought were linked to this bizarre atmospheric event.

Some witnesses were said to see "white particles" swirling through the air; theories ranged from a chemical attack or experimental weapon to drone-related chemical dispersals and references to historical military experiments, such as the infamous 1950s "Operation Sea-Spray."

Fuel to the fire were added when videos and posts, hundreds of thousands in number, began circulating on social media sites like TikTok and X (formerly Twitter) speculating on the origin of the fog. Hashtags like #ToxicFog went trending for days. Hysteria created a self-reinforcing loop in which every post spurred further scrutiny and fear.

Scientific Explanation of the Dense Mysterious Fog

1. What is Fog?

Fog is essentially a low-lying cloud formed when the air temperature cools to its dew point, causing water vapor to condense into tiny droplets or ice crystals. Several types of fog—advection fog, radiation fog, and valley fog—can form depending on conditions such as warm, moist air moving over cooler land or when temperatures plummet rapidly under clear skies.

2. Why the Chemical Smell?

Such chemical-like smell as reported during the occurrence of fog events is sometimes attributed to air pollution. It acts like a sponge, where it absorbs these pollutants, which include sulfur dioxide and nitrogen oxides, among others, that emit from industries. This mixture, therefore, leads to a stench that could be mistaken as unnatural or even toxic.

Also Read: Health Concerns Rise As US, Canada, and UK Come Under The Blanket Of Thick, Dense, Toxic Fog

3. What are the Health Concerns?

High moisture levels from fog can significantly exacerbate symptoms related to respiration, but especially in already predisposed asthmatics and allergy patients. The connection of these symptoms with actual fever, stomach cramps, and puffy eyes is too remote. Experts assume that the irritating effects of entrapped pollutants trapped in fog tend to affect more the eyes and throat rather than the rest of the body affected by some report.

Psychological Effects of Mass Panic Caused by Social Media

Social media amplified a natural weather event into a health epidemic. It made the personal experience of individuals become a cause for fear and speculation, a domino effect.

According to psychologists, this is a concept of selective perception, wherein once people's attention is drawn to environmental anomalies, they begin to notice them. This mirrors earlier panics, such as the Seattle windshield pitting panic of 1954. Then, atomic bomb testing caused fear in many and started to have people looking at their windshields for small marks that they had not seen before. Likewise, postings on the strangeness of the fog probably increased public awareness and suspicion, with people looking to attach unrelated symptoms to the phenomenon.

The fog hysteria shares a commonality with other instances of mass panic, such as the "drone sightings" of recent years or the Cold War-era fears of biological warfare.

Also Read: Mysterious Fog Is Making Americans Sick

These events underscore how fear can cloud judgment, especially when amplified by social media and sensationalist headlines. While historical cases, such as "Operation Sea-Spray," offer concrete evidence of the existence of unethical experiments, the jump from a natural weather condition to theories of chemical attacks exemplifies a more modern trend of connecting unrelated dots, all wonderfully seeded in distrust and anxiety.

Despite the swirling rumors, meteorologists and scientists are in agreement that the mysterious fog is not as alarming as it seems. It is well known that fog traps and amplifies pollutants, especially in urban and industrial regions. Moreover, winter months are the most conducive for fog formation, so its recent prevalence is unsurprising.

On the other hand, environmentalists advise that the fog should wake everyone up to increased levels of pollution. The reported odors and health irritations could be just symptoms of far deeper systemic issues like industrial emissions and lack of control over air quality.

The authorities must be transparent in their communication to combat misinformation and allay public fears. Governments and environmental agencies must provide timely updates on weather phenomena, air quality, and health risks. Initiatives like real-time pollutant tracking and public education campaigns can help demystify natural occurrences while addressing valid environmental concerns.

The mysterious Canada fog is a compelling case study in how environmental events intersect with psychology and societal dynamics. While rooted in natural phenomena, the fog became a vessel for collective fears, amplified by modern technology and historical anxieties.

In this information era where communication occurs at an almost lightning pace, the fog becomes a metaphor that reminds everyone about scientific literacy, environmental responsibility, and an effective balance when considering public concern. Whether perceived as a marvel of nature or as a tale that serves to teach, it left a very powerful mark in people's minds.

The Supreme Court of India has slammed the steep mark-ups private hospitals charge for cancer medicines, describing excessive pricing as “loot” and “dacoity” as it considers whether tighter regulations are needed to protect patients.

During a hearing on October 27, a bench of Justices Vikram Nath and Sandeep Mehta reserved its verdict on petitions seeking stronger controls on the prices of medicines.

The court highlighted the financial burden faced by people who need life-saving treatment, especially those battling cancer, and questioned whether the government’s current pricing framework protects patients from excessive healthcare costs.

Cancer Injection Costs ₹11,000 But Billed At ₹1.3 lakh

Also read: India Caps Cancer Drug Trade Margins At 30%; Patients May Save Rs 2,500 Crore Annually

The Court was hearing a public interest litigation (PIL) filed by advocate Kishan Chand Jain who sought seeking mandatory generic drug prescriptions, stricter initial price controls on non-scheduled medicines, and statutory margin caps on medical devices under the Drug Price Control Order (DPCO).

One example cited by the court is of a medicine distributor whose wife was undergoing cancer treatment at a prominent private hospital.

According to the account presented during the hearing, the distributor offered to procure a chemotherapy injection at his dealer price of ₹11,000, but the hospital charged ₹1.3 lakh for the same medicine.

“Can you show any justification for this loot, please? Why this difference? Where does the money go?” the bench asked.

The judges also questioned the pricing of routine hospital supplies. A saline drip line with a cost ₹15 was reportedly being billed to patients at ₹250.

These examples raised questions about how medicine procurement costs, manufacturer discounts, hospital operating expenses and final patient bills are accounted for.

The Court also addressed Centre's recent decision to cap trade margins for anti-cancer drugs at 30 percent but how nearly 90 percent of medicines available in the market remain outside the purview of the Drug Price Control Order (DPCO).

"Why is the DPCO in place at all? The government is allowing this to happen. There have been three parliamentary committees on this. And their outcome is not very convenient to people who pull the strings, let us tell you," the Bench remarked.

Medicine Price Caps Under Scrutiny

Also read: 137 Cancer Drugs To Cost Up To 70% Less From November 9: NPPA Caps Trade Margins

India regulates prices of scheduled medicines under the Drugs (Prices Control) Order, 2013. The government has also introduced trade margin limits for a few anti-cancer medicines.

During the hearing, the Centre said trade margins on 137 anti-cancer medicines had been capped at 30% of the maximum retail price (MRP), a measure it estimated could save patients around ₹2,500 crore annually.

The court questioned why such interventions were limited to only a few medicines and whether a bigger and more comprehensive drug regulation was needed.

The petitions seek measures including mandatory generic prescriptions, controls on the initial prices of non-scheduled medicines and limits on trade margins for medical devices.

Hospitals And Government Raise Concerns

Representing private hospitals, senior advocate Mukul Rohatgi argued that healthcare institutions must maintain round-the-clock infrastructure and cover substantial operating costs. He also raised concerns about patients bringing medicines from outside, including the risk of counterfeit products.

The Centre maintained that medicine pricing policy must balance affordability with investment, competition and the sustainability of the pharmaceutical sector.

Additional Solicitor General Aishwarya Bhati told the court that the government continued to review its rules. The bench questioned whether these considerations addressed patients’ limited bargaining power when they need life-saving treatment.

"Your calibration is too wayward. ₹11,000 to ₹1,30,000 is no calibration. When you talk of patients and life, should we have such capitalistic thinking. Hospitals can survive through other means. Not through this dacoity,” the bench remarked, according to reports of the proceedings.

The Supreme Court has reserved its verdict. Until the order is delivered, no new price cap should be assumed. The court’s decision could influence future regulation of medicine prices and hospital mark-ups.

The US Centers for Disease Control and Prevention (CDC) recently released a report that stated drug-resistant infections are causing an estimated 50,800 deaths and 9.7 million infections annually in the United States.

Common bacterial infections are usually treated with antibiotics but some germs develop the ability to resist the medicines designed to fight them. This is a grave threat to public health.

The agency has classified four pathogens as urgent threats, warning that resistance to antibiotics and antifungal medicines is making some infections difficult to treat.

The CDC’s 2026 Antimicrobial Resistance Threats Report, released on October 27, is based on data from 2023. It examines 19 drug-resistant bacterial and fungal threats, categorising them as urgent, serious or concerning based on factors including their effects, spread, preventability and the availability of effective treatments.

“Antimicrobial resistance threatens modern medicine and puts millions of Americans at risk every year,” CDC Director Dr Erica Schwartz said in a statement.

Drug-Resistant Pathogens That Pose The Greatest Risks

The federal health agency has identified the following four pathogens as requiring urgent and aggressive action.

Candida auris

Candida auris, a fungus that can cause severe infections, includes potentially fatal bloodstream infections, particularly in people who are already seriously ill. It is a major concern in hospitals and nursing homes because it can be transmitted through contaminated surfaces and medical equipment like catheters, and some strains resist multiple antifungal medicines.

The CDC recorded 4,523 cases in the United States in 2023. Cases increased by more than 50% between 2022 and 2023, according to the report.

People can carry the fungus on their skin without developing symptoms, allowing it to spread in healthcare environments.

Drug-resistant gonorrhoea

Gonorrhoea is a sexually transmitted infection caused by the bacterium Neisseria gonorrhoeae. The infection can be treated with antibiotics, but the bacterium has developed resistance to several medicines.

The CDC estimates that approximately 787,000 drug-resistant gonorrhoea infections occurred in the US in 2023. Untreated gonorrhoea can cause pelvic inflammatory disease, infertility and other reproductive complications.

The growing resistance leaves healthcare providers with fewer reliable treatment options, making surveillance and the development of new antibiotics important.

Also read: 'It’s The Best-Studied Vaccine In Human History': Former CDC Adviser Busts Common Myths About COVID Vaccines

Carbapenem-resistant Enterobacterales (CRE)

CRE are a group of bacteria, including some strains of Escherichia coli and Klebsiella, that resist carbapenems, a powerful class of antibiotics often reserved for difficult-to-treat infections.

These bacteria can cause infections in the bloodstream, lungs and urinary tract. They pose a particular risk to hospital patients, especially those with weakened immune systems, catheters or ventilators.

In 2023, CRE caused an estimated 14,878 infections among hospitalised patients and 1,252 deaths in the US. Drug resistance can leave doctors with few effective treatment options.

Carbapenem-resistant Acinetobacter

Carbapenem-resistant Acinetobacter is another group of bacteria that can cause serious infections, particularly among critically ill patients in healthcare settings. These include pneumonia, bloodstream infections and infections associated with wounds.

Resistance to carbapenems makes these infections difficult to treat and can increase the risk of complications and death.

Antimicrobial Resistance Is A Growing Concern

The CDC is also monitoring six more kinds of germs. One is drug-resistant ringworm, a fungal skin infection that is becoming harder to treat with standard fungal medications. The health body says misusing over-the-counter antifungal creams and using steroid-antifungal cream combinations may contribute to resistance.

Antimicrobial resistance occurs when bacteria, fungi and other pathogens develop the ability to survive medicines designed to kill them or stop their growth. This can happen through genetic changes and the spread of resistance mechanisms between microbes. The unnecessary or inappropriate use of antimicrobial medicines can accelerate the process.

The consequences extend beyond infections themselves. Drug resistance can prolong hospital stays, increase healthcare costs and make procedures like surgery, cancer treatment and organ transplantation riskier because these depend on effective medicines to treat infections.

Infections commonly associated with healthcare settings accounted for more than 42,000 deaths and nearly $12 billion in US healthcare costs in 2023, according to the report.

The CDC also reported progress in some areas. Clostridioides difficile, a bacterium associated with severe diarrhoea and often linked to antibiotic use, was downgraded from an urgent to a serious threat. The agency attributed the change partly to improvements in infection prevention and antibiotic stewardship.

However, the CDC cautioned that its methods and data sources changed substantially since its previous report. The latest estimates therefore cannot be directly compared with older figures to determine how much the overall burden has increased.

How To Prevent Antibiotic Resistance?

The CDC recommends using antibiotics only when prescribed by a healthcare professional and taking them exactly as directed. Antibiotics do not treat viral infections like the common cold or flu.

Hand hygiene, vaccinations, infection-control measures in healthcare environments including appropriate prescribing practices can also help limit the spread of resistant pathogens.

Joshua, 27, was diagnosed with autism at two and a half. He was nonverbal and experienced severe anxiety, while getting a full night's sleep remained a struggle for years.

An experimental drug called L1-79, touted as ‘Ozempic Of Autism' has reportedly brought significant improvements in his condition, according to the Daily Mail, raising interest in its potential to address core features of autism spectrum disorder (ASD).

How Did The Drug L1-79 Help Joshua?

Developed by Yamo Pharmaceuticals, L1-79 is an oral drug designed to target core symptoms of autism.

Joshua’s psychiatrist of eight years, Dr. Eric Bartky, an autism specialist involved in the US FDA trial of L1-79, asked his parents Linda and Jim Turteltaub to consider trying the drug.

The decision involved uncertainty. Taking part in the trial required Joshua to stop all his other medications, and the potential side effects of the new treatment were not fully known. Despite these concerns, his parents decided in 2015 to give it a try.

“We just wanted something to address the issues, to try and get him better so that he can at least communicate with us,” Linda said.

According to the report, Joshua showed his first notable improvement within a week of beginning treatment.

Also read: Autism Care Begins Early: Why the First 1,000 Days Matter Most, Says AIIMS Expert

How Does L1-79 Work?

Yamo Pharmaceuticals describes L1-79 as a selective inhibitor of tyrosine hydroxylase, an enzyme involved in the production of dopamine and norepinephrine.

The drug is intended to lower the production of these chemical messengers in an effort to regulate pathways that may contribute to sensory overload and social withdrawal in people with autism.

Dr. Bartky said the drug differs from existing approaches because it aims to address core features of autism, including social interaction and communication.

“What makes L1-79 different is that L1-79 treats the core symptoms of autism, things like socialization and communications, things that go along with that like eye contact, reciprocal conversation, nonverbal communication, such as reading social nuance. These are things that are extremely important for a person's emotional growth and functioning in society.”

The response to treatment has varied among Dr. Bartky's patients, reflecting the wide range of symptoms associated with ASD.

What Is The Status Of L1-79 Clinical Trials?

Read More: Stem Cell Therapy For Autism: What India’s New Advisory Means For Patients

There is currently no single medication that treats all the core features of autism spectrum disorder. Several medications are prescribed to manage particular behavioral patterns and associated conditions.

L1-79 is being investigated as a potential treatment that could address autism's underlying neurological features. The Daily Mail reported that 116 patients had participated in L1-79's three clinical trials.

The drug has received Fast Track designation from the US Food and Drug Administration (FDA). This program is intended to facilitate the development and review of treatments for serious conditions that address unmet medical needs.

Although the designation does not shorten the clinical trial process, it can make a drug eligible for priority review. Under this pathway, the FDA aims to complete its review within six months, compared with the standard 10-month timeline.

Are There Any Safety Concerns?

Dr. Bartky also pointed to what he described as L1-79's safety profile.

Some existing medications can cause serious side effects, including dyskinesia, which involves involuntary movements that can sometimes be permanent; metabolic syndrome, a group of conditions associated with increased risks of heart disease, stroke and type 2 diabetes; and hypertension. Dr. Bartky said L1-79 had “not had one single serious side effect.”